| 1 |
33904654 | Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib. | 2022 Feb |
3 |
| 2 |
34074804 | Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations. | 2022 Jan 1 |
1 |
| 3 |
34348357 | What management for epidermal growth factor receptor-mutated non-small-cell lung cancer, with squamous cell transformation and T790M-acquired resistance mechanisms? A Case report and review of literature. | 2022 Jan 1 |
1 |
| 4 |
34352998 | miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37. | 2022 Apr |
7 |
| 5 |
34633106 | A novel cyclic NP1 reveals obstruction of EGFR kinase activity and attenuation of EGFR-driven cell lines. | 2022 Feb |
2 |
| 6 |
34648945 | Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors. | 2022 Feb |
1 |
| 7 |
34707044 | Rhabdomyolysis Caused by Gefitinib Overdose. | 2022 May 15 |
1 |
| 8 |
34726958 | Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). | 2022 Jan 20 |
2 |
| 9 |
34738874 | AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1. | 2022 Jan |
2 |
| 10 |
34861243 | Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. | 2022 Jan |
1 |
| 11 |
34919024 | Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway. | 2022 Jan |
2 |
| 12 |
34953624 | Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial. | 2022 Apr |
1 |
| 13 |
34987800 | Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report. | 2022 Feb |
1 |
| 14 |
34994998 | Curcumin suppresses cell proliferation and triggers apoptosis in vemurafenib-resistant melanoma cells by downregulating the EGFR signaling pathway. | 2022 Apr |
1 |
| 15 |
34996416 | A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells. | 2022 Jan 7 |
2 |
| 16 |
34998839 | Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis. | 2022 Feb 15 |
1 |
| 17 |
35014626 | Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial. | 2022 Jan 11 |
2 |
| 18 |
35046665 | Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study. | 2022 |
2 |
| 19 |
35068940 | Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study. | 2022 |
2 |
| 20 |
35078385 | Black phosphorus nanoparticles for dual therapy of non-small cell lung cancer. | 2022 Jul |
1 |
| 21 |
35105467 | [Drug-drug interactions of tyrosine kinase inhibitors in treatment of non-small-cell lung carcinoma]. | 2022 Mar |
1 |
| 22 |
35122447 | Effects of the epidermal growth factor receptor inhibitor, gefitinib, on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes. | 2022 Jun |
1 |
| 23 |
35158954 | Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer. | 2022 Jan 28 |
1 |
| 24 |
35185556 | Blimp-1 Upregulation by Multiple Ligands via EGFR Transactivation Inhibits Cell Migration in Keratinocytes and Squamous Cell Carcinoma. | 2022 |
2 |
| 25 |
35188360 | The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer. | 2022 Feb 22 |
1 |
| 26 |
35216325 | A Transcriptomic Approach to Elucidate the Mechanisms of Gefitinib-Induced Toxicity in Healthy Human Intestinal Organoids. | 2022 Feb 17 |
3 |
| 27 |
35235599 | Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells. | 2022 |
3 |
| 28 |
35240162 | PTPIP51 inhibits non-small-cell lung cancer by promoting PTEN-mediated EGFR degradation. | 2022 May 15 |
1 |
| 29 |
35303882 | Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression. | 2022 Mar 18 |
1 |
| 30 |
35305596 | Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study). | 2022 Mar 19 |
1 |
| 31 |
35319011 | MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer. | 2022 Mar 22 |
3 |
| 32 |
35326664 | Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. | 2022 Mar 15 |
1 |
| 33 |
35330996 | Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis. | 2022 May |
5 |
| 34 |
35360423 | Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA-IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study. | 2022 |
1 |
| 35 |
35399718 | An insulin growth factor-I/II-neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth. | 2022 |
1 |
| 36 |
35399731 | LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma. | 2022 |
3 |
| 37 |
35402377 | Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer. | 2022 |
2 |
| 38 |
35408854 | Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth. | 2022 Mar 23 |
1 |
| 39 |
35433830 | Recombinant Prolidase Activates EGFR-Dependent Cell Growth in an Experimental Model of Inflammation in HaCaT Keratinocytes. Implication for Wound Healing. | 2022 |
1 |
| 40 |
35433927 | An advanced non-small cell lung cancer patient with EGFR and KRAS mutations, and PD-L1 positive, benefited from immunotherapy: a case report. | 2022 Mar |
1 |
| 41 |
35445730 | EGFR inhibition reverses epithelial‑mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells. | 2022 Jun |
1 |
| 42 |
35446957 | First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study. | 2022 Apr 22 |
1 |
| 43 |
35462930 | Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports. | 2022 |
2 |
| 44 |
35463301 | Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling. | 2022 |
4 |
| 45 |
35468939 | CRL2KLHDC3 mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression. | 2022 May |
2 |
| 46 |
35478210 | Decoy receptor 3 is involved in epidermal keratinocyte commitment to terminal differentiation via EGFR and PKC activation. | 2022 Apr |
1 |
| 47 |
35481881 | Targeted Drug/Gene/Photodynamic Therapy via a Stimuli-Responsive Dendritic-Polymer-Based Nanococktail for Treatment of EGFR-TKI-Resistant Non-Small-Cell Lung Cancer. | 2022 Apr 28 |
1 |
| 48 |
35488047 | Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib. | 2022 Apr 29 |
1 |
| 49 |
35522668 | The efficacy of T790M mutation testing in liquid biopsy-Real clinic data. | 2022 |
1 |
| 50 |
35530301 | Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer. | 2022 |
3 |